Slide 1: Exchange filing cover letter for Q1 FY24 presentation
August 01, 2023 The National Stock Exchange of India Limited BSE Limited Exchange Plaza Phiroze Jeejeeboy Towers Bandra Kurla Complex, Dalal Street, Bandra (E), Mumbai - 400 051 Mumbai- 400 001 (SYMBOL: THYROCARE) (SCRIP CODE 539871) Dear Sirs/Madam, Sub: Presentation- unaudited financial results fo
Slide 2: Thyrocare Earnings Presentation Q1 FY24
S Thyrocare Tests you can trust — Thyrocare Earnings Presentation Ql FY24
Slide 3: Safe harbour statement
Safe harbour statement Statements in this presentation describing the Company’s performance may be “forward looking statements” within the meaning of applicable securities laws and regulations. Actual results may differ materially from those directly or indirectly expressed, inferred or implied.Impo
Slide 4: Agenda
Agenda ie What Is Keeping Us Busy 02 Performance Highlights 03 Financial Performance 04 Going Forward Strategy 02
Slide 5: New product launches: Jaanch, Her Check & Troponin I
New product launches: Jaanch, Her Check & Troponin I Jaanch Her Check Troponin | . 360 DEGREE CARE CHECK —— For Every Phase Of —— Jaanth HER LIFE - Bi . € For a closer look LG at your health with A Doctor-Curated Specialised Packages All Under One Roof v Soeores D Heart ) Fever ah Cancer Skin Care O
Slide 6: Raising the bar on quality
Raising the bar on quality Sample iS Collection Yy 98% On-time collection (60 Min slot adherence) » 4 95% SOP Adherence “Immunoassay machines; Mid Mile Vv 95% Cold Chain Adherence Average Logistics TAT Of 12 Hours To Reach Nearest Lab » 4 Sample rejection of 1.5% CPM - Complaints per million sample,
Slide 7: Agenda: Performance Highlights
Agenda 01 What Is Keeping Us Busy ya Performance Highlights 03 Financial Performance 04 Going Forward Strategy 0S
Slide 8: Quarter health-check
Quarter health-check YoY TTL Consolidated Revenue YoY TTL Standalone Revenue S YoY Normalized EBIDTA* — *Note: Normalized EBIDTA is at consolidated level and is before ESOPs and provisions for doubtful debts YoY NHL Standalone Revenue Normalized EBITDA'% 06
Slide 9: 6% growth in YoY revenue; 15% growth in YoY N.EBITDA
6% growth in YoY revenue ; 15% growth in YoY N.EBITDA Consolidated Revenue (INR Cr) Normalized EBITDA (INR Cr) perenne eens PGi scoeeeracweny gece cece c cs PG aeesercceevecay 135.0 417 1359 949 i 40.6 1278 128.0 : 36.2 5 349 N N N foe} so fos Ke} N v oO = fe) is) N st = - = = “ xt ~ a 6 S = = om =
Slide 10: 16% YoY growth in Franchise business, Partnerships down
16% YoY growth in Franchise business, Partnerships down because of API & B2G \\ \V \\ VY Pathology Revenue (Rs Cr) 38 38 38 of API & B2G Note: All numbers except QI FY24 refers to non-covid numbers ; Pathology excludes Materials & Others ql Q2 Q3 Q4 Ql FY23 FY23 FY23 FY23 FY24 WW2Cr 117Cr 109Cr 119C
Slide 11: Agenda: Financial Performance
Agenda 01 What Is Keeping Us Busy 02 Performance Highlights (KE Financial Performance 04 Going Forward Strategy og
Slide 12: Standalone quarterly financials
Quarter Variance % Pathology revenue grew by 4% YoY, INR crore Q1 FY24 Q4 FY23 Q1 FY23 Seq. YOY while the Franchise business grew by Revenue from operations 123.61 124.82 119.24 -1% 4% 16%, overall growth impacted due to Cost of materials consumed/ sold (35.87) (39.64) (38.26) -10% -6% closure of MC
Slide 13: NHL quarterly financials
Quarter Variance % NHL Revenue grew 29% Y-o-Y on INR crore Q1 FY24 Q4 FY23 Q1 FY23 Seq. YOY account of new centers at Surat and Revenue from operations 11.02 11.06 8.55 0% 29% Baroda starting from Q2 FY23 and Cost of materials consumed/ sold (2.20) (2.11) (1.24) 4% 78% increase in FDG/PSMA sales Gro
Slide 14: Consolidated quarterly financials
Quarter Variance % Revenue from operations INR crore Q1 FY24 Q4 FY23 Q1 FY23 Seq. YOY include Pulse Hitech Revenue from operations 134.89 135.88 127.79 -1% 6% Cost of materials consumed/ sold (38.07) (41.75) (39.50) -9% -4% ESOPs program to retain Gross margin 96.82 94.13 88.29 3% 10% talent introdu
Slide 15: Agenda: Going Forward Strategy
Agenda 01 What Is Keeping Us Busy 02 Performance Highlights 03 Financial Performance Going Forward Strategy 13
Slide 16: Vision & Mission
Vision & Mission Mission To be the best provider of diagnostic solutions to all stakeholders in healthcare - be it a single doctor, polyclinics, a health check up patient, a diagnostic lab, a nursing home, a large hospital, medical and health tech platforms or the Government To ensure everyone has a
Slide 17: Our strategy remains to be a B2B service provider
Our strategy remains to be a B2B service provider with an affordable value driven model based on scale efficiencies G Thyrocare Tests you can trust Franchise Partnership +B2G > Mom & Pop collection centers H > Online diagnostics aggregators > Local labs ! > Healthcare platforms > Nursing homes & hos
Slide 18: Going forward - Key pillars of growth
Going forward - Key pillars of growth Franchise > Going deeper into India with focused test menu > Strengthening our existing Franchise network with focus on large service providers Public & Private Partnerships > Focus on TB and Infectious Disease along with large screening programs run by Health b
Slide 19: Thank You
Q Thyrocare Tests you can trust Thank You Disclaimer This presentation is for information purposes only and it contains genera! background information about the Company’s activities. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements on the basis